Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by JayjayUSA12007on Dec 02, 2022 4:14am
440 Views
Post# 35145650

Sortilin and Eyesight - side effect vs efficacy

Sortilin and Eyesight - side effect vs efficacyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338683/

This study is evidence that Sortilin is associated with the eyes.
Since TH902 is designed to attach to Sortilin, it causes the side effect to the eyes.
On the other hand, this so-called side effect indirectly shows that TH902 works as expected on human, since most cancer cells have Sortilin expressed on its surface.

As such, this is the question of Risk vs Benefits. The new trial protocol amendment is to strike a balance between them.

Furthermore, as TH902 is designed as salvage therapy, its benefits would likely weight more than potential risks, given these patients' conditions.
<< Previous
Bullboard Posts
Next >>